Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-8554 in vasomotor symptoms
NCT02803268Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jun 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elismetrep in vasomotor symptoms (4 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoints: Safety and Tolerability as measured by vital signs at 21 days and Adverse Events at 21 days. Started Jun 2016; status: completed.
02
Drugs
elismetrep
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT02803268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02803268.